ReviewMaterials today. Bio2025
Novel therapeutic strategies and recent advances in gut microbiota synergy with nanotechnology for colorectal cancer treatment.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Dietary Terpenoids in Advancing Biofilm-Mediated Cancer Prevention: Antibiofilm Cascade, Molecular Crosstalk, and Nano-Facilitated Functional Delivery.Cell biochemistry and function · 2026Review
- Targeting tumor-associated bacteria in digestive system cancers: carcinogenic mechanisms and nano-regulate platform design.Journal of nanobiotechnology · 2026Review
- Biomineral Complex with Probiotic and Detoxifying Properties for Recovery After Radiotherapy.International journal of molecular sciences · 2026Article
- Timekeepers of the gut: host circadian rhythms and microbial modulators.Life metabolism · 2026Review
- Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy.Journal of nanobiotechnology · 2026Review
- Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Materials today. Bio · 2025Review
- Microbiota-driven epigenetic modifications in gastrointestinal cancer: Implications for pathogenesis and therapeutic strategies.World journal of microbiology & biotechnology · 2025Review
- Metabolic interactions: how gut microbial metabolites influence colorectal cancer.Frontiers in microbiology · 2025Review
- Camptothecin-PHA nanoparticles attenuate drug-induced gut microbiome dysbiosis and metabolic toxicity.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last two decades, molecular biology advances have revealed the gut microbiota's active and crucial role in colorectal cancer (CRC) pathogenesis and its dysregulation during tumorigenesis. This understanding has underscored the urgency of exploring novel therapeutic approaches to address the challenges posed by CRC. Among these approaches, nanosynergistic therapies, with their potential to modulate the gut microbiota, increase drug bioavailability and stability, and reduce side effects, have emerged as a promising avenue. Furthermore, the efficacy of nanotechnology-based approaches can be enhanced by combining them with different therapeutic methods, including chemotherapy, radiotherapy, immunotherapy, photothermal therapy, and sonodynamic therapy. Herein, recent progress in nano synergistic therapy has been reviewed, focusing on the synergy between gut microbiota and nanotechnology in CRC treatment. Additionally, the diverse applications of nanoparticles have been analyzed to provide innovative ideas and effective solutions for developing highly effective CRC treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.